Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829 · see citing works

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 313 · see citing works

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277 · see citing works

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227 · see citing works

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214 · see citing works

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

Jones, H., Stafford, L. E., Swaisland, H., & Payne, R. K. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00014-6 · Cited by 63 · see citing works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,780 · see citing works

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · see citing works

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · see citing works

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793 · see citing works

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766 · see citing works

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · see citing works

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Costa, D. B., Shaw, A. T., Ou, S. I., Solomon, B., Riely, G. J., Ahn, M., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 603 · see citing works

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 601 · see citing works

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Lin, N., Carey, L., Liu, M., Younger, J., Come, S. E., Ewend, M. G., Harris, G. J., Bullitt, E., den Abbeele, A. D. V., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 459 · see citing works

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid

Pentsova, E. I., Shah, R. H., Tang, J., Boire, A. A., You, D., Briggs, S. R., Omuro, A. M. P., Lin, X., Fleisher, M., Grommes, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6487 · Cited by 415 · see citing works

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.014 · Cited by 361 · see citing works

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 358 · see citing works

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 355 · see citing works

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 340 · see citing works

MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity

Teplyuk, N. M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E. L., Smolsky, M., Kim, R. Y., Saria, M. G., Pastorino, S., Kesari, S. P., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos074 · Cited by 302 · see citing works

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282 · see citing works

Leptomeningeal metastasis from systemic cancer: Review and update on management

Wang, N., Bertalan, M. S., & Brastianos, P. K. (2017) · Cancer · doi:10.1002/cncr.30911 · Cited by 262 · see citing works

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 255 · see citing works

Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 219 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224 · see citing works

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 216 · see citing works

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · see citing works

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era

Remón, J., Rhun, É. L., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 193 · see citing works

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178 · see citing works

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176 · see citing works

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era

Park, J. H., Kim, Y. J., Lee, J., Lee, K., Kim, J. H., Bang, S., Chung, J.-H., Js, K., & Lee, J. S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.022 · Cited by 173 · see citing works

Therapy of leptomeningeal metastasis in solid tumors

Mack, F., Baumert, B. G., Schäfer, N., Hattingen, E., Scheffler, B., Herrlinger, U., & Glas, M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.004 · Cited by 172 · see citing works

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 165 · see citing works

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 161 · see citing works

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Sun, M., Behrens, C., Feng, L., Ozburn, N. C., Tang, X., Yin, G., Komaki, R. U., Varella‐Garcia, M., Hong, W. K., Aldape, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2921 · Cited by 152 · see citing works

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150 · see citing works

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Zeng, Q., Wang, J., Cheng, Z., Chen, K., Johnström, P., Varnäs, K., Li, D. Y., Yang, Z. F., & Zhang, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01073 · Cited by 151 · see citing works

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V., de Groot, J., Glitza, I. C., Herlyn, M., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12538 · Cited by 150 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain

Jamal‐Hanjani, M., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2529 · Cited by 146 · see citing works

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 141 · see citing works

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138 · see citing works

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

Sullivan, I., & Planchard, D. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015617355 · Cited by 133 · see citing works

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 130 · see citing works

Leptomeningeal Metastasis from Non–Small Cell Lung Cancer and Current Landscape of Treatments

Ozcan, G., Singh, M., & Vredenburgh, J. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1585 · Cited by 127 · see citing works

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 125 · see citing works

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

Oxnard, G. R., Morris, M. J., Hodi, F. S., Baker, L. H., Kris, M. G., Venook, A. P., & Schwartz, L. H. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs353 · Cited by 125 · see citing works

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group

Umemura, S., Tsubouchi, K., Yoshioka, H., Hotta, K., Takigawa, N., Fujiwara, K., Horita, N., Segawa, Y., Hamada, N., Takata, I., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.002 · Cited by 122 · see citing works

Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma

Zhao, J., Chen, M., Zhong, W., Zhang, L., Li, L., Xiao, Y., Nie, L., Hu, P., & Wang, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.004 · Cited by 121 · see citing works

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

Lee, E., Keam, B., Kim, D., Kim, T. M., Lee, S., Chung, D. H., & Heo, D. S. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318294c8e8 · Cited by 121 · see citing works

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy

Zeng, Y.-D., Liao, H., Qin, T., Zhang, L., Wei, W.-D., Liang, J.-Z., Xu, F., Dinglin, X.-X., Ma, S.-X., & Chen, L.-K. (2015) · Oncotarget · doi:10.18632/oncotarget.3187 · Cited by 112 · see citing works

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110 · see citing works

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer

Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106 · see citing works

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

Jackman, D. M., Cioffredi, L. A., Jacobs, L., Sharmeen, F., Morse, L. K., Lucca, J. V., Plotkin, S. R., Marcoux, P. J., Rabin, M. S., Lynch, T. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2886 · Cited by 101 · see citing works

Leptomeningeal Disease

Groves, M. D. (2010) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2010.08.006 · Cited by 100 · see citing works

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

Tang, X., Varella‐Garcia, M., Xavier, A. C., Massarelli, E., Ozburn, N. C., Moran, C. A., & Wistuba, I. I. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0032 · Cited by 99 · see citing works

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Masuda, T., Hattori, N., Hamada, A., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Fujitaka, K., Haruta, Y., Murai, H., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1555-6 · Cited by 97 · see citing works

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee, J., Choi, Y., Han, J., Park, S., Jung, H. A., Su, J.-M., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.018 · Cited by 90 · see citing works

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

Shukuya, T., Takahashi, T., Naito, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Murakami, H., Harada, H., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.007 · Cited by 89 · see citing works

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86 · see citing works

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 80 · see citing works

Leptomeningeal metastasis

Taillibert, S., & Chamberlain, M. C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00013-x · Cited by 81 · see citing works

Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement

Takeda, M., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c28e7 · Cited by 80 · see citing works

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment

Remón, J., & Besse, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00088 · Cited by 79 · see citing works

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y. H., Ikemi, Y., Sakamori, Y., Mio, T., Katsura, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1691-z · Cited by 79 · see citing works

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 78 · see citing works

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

Kawamura, T., Hata, A., Takeshita, J., Fujita, S., Hayashi, M., Tomii, K., & Katakami, N. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2759-y · Cited by 77 · see citing works

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Baik, C. S., Chamberlain, M. C., & Chow, L. Q. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000615 · Cited by 77 · see citing works

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

Tam, I. Y. S., Leung, E. L., Tin, V. P., Chua, D. T.-T., Sihoe, A. D., Cheng, L., Chung, L.-P., & Wong, M. P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1219 · Cited by 76 · see citing works

CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives

Berger, L. A., Riesenberg, H., Bokemeyer, C., & Atanackovic, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.004 · Cited by 74 · see citing works

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Zeng, Y.-D., Zhang, L., Liao, H., Liang, Y., Xu, F., Liu, J., Dinglin, X.-X., & Chen, L.-K. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.3.909 · Cited by 72 · see citing works

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Wang, Q., Zhang, P., Li, Z., Feng, X., Lv, C., Zhang, H., Xiao, H., Ding, J., & Chen, X. (2019) · Theranostics · doi:10.7150/thno.31683 · Cited by 72 · see citing works

EGFR mutation status in brain metastases of non-small cell lung carcinoma

Burel‐Vandenbos, F., Ambrosetti, D., Coutts, M., & Pédeutour, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0990-5 · Cited by 72 · see citing works

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

Lee, H., Chung, T.-S., Ting, L., Tsai, J., Chen, S.-W., Chiou, J., Leung, H. W.-C., & Liu, H. E. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-181 · Cited by 65 · see citing works

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

Aw, D. C., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12687 · Cited by 69 · see citing works

Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead

Ulahannan, D., Khalifa, J., Finn, C. F., & Lee, S. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx481 · Cited by 63 · see citing works

Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose Erlotinib

Dhruva, N., & Socinski, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0963 · Cited by 64 · see citing works

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

Zhang, J., Yu, J., Sun, X., & Meng, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.019 · Cited by 63 · see citing works

Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature

Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0319-6 · Cited by 60 · see citing works

Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Qiu, B., Liang, Y., Li, Q.-W., Liu, G.-H., Wang, F., Chen, Z., Liu, M., Zhao, M. D., & Liu, H. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.002 · Cited by 60 · see citing works

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

Baek, M. Y., Ahn, H. K., Park, K. R., Park, H.-S., Kang, S. M., Park, I., Kim, Y. S., Hong, J., Sym, S. J., Park, J., et al. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.158 · Cited by 54 · see citing works

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure

Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53 · see citing works

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

Zhao, J., Ye, X., Xu, Y., Chen, M., Zhong, W., Sun, Y., Yang, Z., Zhu, G., Gu, Y., & Wang, M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3155-y · Cited by 53 · see citing works

Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature

How, J., Mann, J., Laczniak, A. N., & Baggstrom, M. Q. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.013 · Cited by 52 · see citing works

High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer

Hata, A., Kaji, R., Fujita, S., & Katakami, N. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d899bb · Cited by 50 · see citing works

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement–Positive Non–Small-Cell Lung Cancer

Kaneda, H., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182843771 · Cited by 50 · see citing works

Targeted Therapies in Brain Metastases

Lin, N. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0276-z · Cited by 49 · see citing works

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Chen, Y., Wang, M., Zhong, W., & Zhao, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.013 · Cited by 48 · see citing works

Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies

Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48 · see citing works

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona, A., Dziadziuszko, R., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.011 · Cited by 47 · see citing works

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well

Kuiper, J. L., & Smit, E. F. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.024 · Cited by 46 · see citing works

Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?

Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45 · see citing works

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung

Conforti, F., Catania, C., Toffalorio, F., Duca, M., Spitaleri, G., Barberis, M. C. P., Noberasco, C., Delmonte, A., Santarpía, M., Lazzari, C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.019 · Cited by 44 · see citing works

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

Ruppert, A.-M., Beau‐Faller, M., Neuville, A., Guérin, É., Voegeli, A.-C., Mennecier, B., Legrain, M., Molard, A., Jeung, M.-Y., Gaub, M.-P., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00162307 · Cited by 44 · see citing works

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study

Zhou, L., He, J., Xiong, W., Liu, Y., Xiang, J., Yu, Q., Liang, M., Zhou, X., Ding, Z., Huang, M., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.003 · Cited by 40 · see citing works

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib

Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Yoshida, H., Yagi, Y., Nakaoku, T., & Mishima, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829cebbb · Cited by 39 · see citing works

Novel approaches to treating leptomeningeal metastases

Grewal, J., Saria, M. G., & Kesari, S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0686-2 · Cited by 39 · see citing works

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38 · see citing works

Erlotinib for the treatment of brain metastases in non-small cell lung cancer

Brower, J. V., & Robins, H. I. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1165206 · Cited by 37 · see citing works

Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.

Panther, L., Schlecht, H. P., & Dezube, B. J. (2005) · PubMed · Cited by 24 · see citing works

Anale intraepitheliale Neoplasie und Analkarzinom

Kreuter, A., Brockmeyer, N. H., & Wieland, U. (2009) · Der Hautarzt · doi:10.1007/s00105-009-1810-5 · Cited by 14 · see citing works

Anal cancer and its precursors in HIV-positive patients: perspectives and management

Berry, J. M., Palefsky, J. M., & Welton, M. L. (2004) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2003.12.003 · Cited by 93 · see citing works

HPV-Associated Anal Cancer in the HIV/AIDS Patient

Wang, C.-C. J., & Palefsky, J. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-030-03502-0_7 · Cited by 62 · see citing works

Anal intraepithelial neoplasia and squamous cell carcinoma in HIV ‐infected adults

Tong, W., Hillman, R. J., Kelleher, A. D., Grulich, A., & Carr, A. D. (2013) · HIV Medicine · doi:10.1111/hiv.12080 · Cited by 42 · see citing works